Porton Pharma Solutions Ltd
SZSE:300363
Net Margin
Porton Pharma Solutions Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | CN |
Market Cap | 8.7B CNY |
Net Margin |
-4%
|
Country | JP |
Market Cap | 776 550.9T JPY |
Net Margin |
-79%
|
Country | US |
Market Cap | 731.8B USD |
Net Margin |
17%
|
Country | DK |
Market Cap | 4T DKK |
Net Margin |
37%
|
Country | UK |
Market Cap | 440.4B GBP |
Net Margin |
-4%
|
Country | US |
Market Cap | 372.2B USD |
Net Margin |
45%
|
Country | US |
Market Cap | 332.3B USD |
Net Margin |
4%
|
Country | UK |
Market Cap | 187.7B GBP |
Net Margin |
13%
|
Country | CH |
Market Cap | 189B CHF |
Net Margin |
20%
|
Country | CH |
Market Cap | 182.7B CHF |
Net Margin |
30%
|
Country | US |
Market Cap | 161.7B USD |
Net Margin |
-1%
|
Profitability Report
View the profitability report to see the full profitability analysis for Porton Pharma Solutions Ltd.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Porton Pharma Solutions Ltd's most recent financial statements, the company has Net Margin of -4.5%.